NEU neuren pharmaceuticals limited

Ann: Update - Notification of buy-back - NEU, page-15

  1. 6,345 Posts.
    lightbulb Created with Sketch. 23046
    ACAD made a “strategic investment” in NEU as part of the July 2018 US licence agreement.
    They acquired 1,330,000 share for A$4m, which was equivalent to ~ US$3m at the time.

    The last sighting of ACAD’s investment in NEU was at 30/06/23. The reported value at that time was US$10,781,000.

    From ACAD accounts, it appears that the company sold all of its holdings in NEU during Q3 last year.

    NEU stock price at 30/06/23 was A$12.25. The price jumped to $14.20 by 21/07/23, following the signing of the global licence between Acadia and Neuren. The stock price then tracked down to A$10.47 on 22/09/23, a 26% decline over that two month period.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$17.67
Change
-0.110(0.62%)
Mkt cap ! $2.230B
Open High Low Value Volume
$17.67 $18.02 $17.58 $5.658M 318.9K

Buyers (Bids)

No. Vol. Price($)
6 344 $17.67
 

Sellers (Offers)

Price($) Vol. No.
$17.69 568 4
View Market Depth
Last trade - 14.42pm 11/08/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.